| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Reply to: ��Predictors of sorafenib benefit in patients with hepatocellular carcinoma��
|
Bruix J.; ANN-LII CHENG; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:31Z |
Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice
|
Tsai C.-L.; Liu W.-L.; Hsu F.-M.; Yang P.-S.; Yen R.-F.; Tzen K.-Y.; ANN-LII CHENG; Chen P.-J.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signaling
|
Hsu W.-T.; Huang C.-Y.; Yen C.Y.T.; ANN-LII CHENG; Hsieh P.C.H. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
|
Bruix J.; ANN-LII CHENG; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
|
Yang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:35Z |
Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; ANN-LII CHENG; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
|
Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Corrigendum to ��Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells�� [Neoplasia (United States) 14 (2012) 463�V475](S1476558612801023)(10.1596/neo.12300)
|
Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer
|
Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG; Lin J.-T.; Shun C.-T.; Wu M.-S. |
